MRNY vs. MRNA

The year-to-date returns for both investments are quite close, with MRNY having a -40.95% return and MRNA slightly higher at -39.61%.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for YieldMax MRNA Option Income Strategy ETF (MRNY) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current MRNY Sharpe Ratio is -1.43, which is comparable to the MRNA Sharpe Ratio of -1.11. The chart below compares the historical Sharpe Ratios of MRNY and MRNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

MRNY's dividend yield for the trailing twelve months is around 209.89%, while MRNA has not paid dividends to shareholders.

The maximum MRNY drawdown since its inception was -80.66%, smaller than the maximum MRNA drawdown of -94.82%. Use the drawdown chart below to compare losses from any high point for MRNY and MRNA. For additional features, visit the drawdowns tool.

The current volatility for YieldMax MRNA Option Income Strategy ETF (MRNY) is 15.37%, while Moderna, Inc. (MRNA) has a volatility of 17.82%. This indicates that MRNY experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.